Transcription of ORAL PD-L1 PROGRAM: INCB86550
{{id}} {{{paragraph}}}
Example: tourism industry
ORAL PD-L1 PROGRAM: INCB86550
N O V E M B E R 1 3 , 2 0 2 1 ORAL PD-L1 PROGRAM: INCB86550 INCB99280 INCB99318 FORWARD LOOKING STATEMENTS2 Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates, and other forward-looking statements, such as statements regarding Incyte s expectations with respect to its oral PD-L1 franchise, including the potential for market growth and the potential treatment benefits and Incyte s expectations regarding ongoing clinical trials and clinical trials to be initiated for INCB86550 , INCB99280, and INCB99318. These forward-looking statements are based on the Company s current expectations and subject to risks and uncertainties that maycause actual results to differ materially, including unanticipated developments in and risks related to: further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID 19 pandemic and measures to address the pandemic on the Company s clinical trials, supply chain and other third-party providers, sales and marketing efforts and business, development and discovery
APPROACH TO CANCER THERAPY 6 INCB86550 INCB99280 INCB99318 Blocking PD-1/PD-L1 interaction is effective in reversing immune suppression by tumor cells1,2 Monoclonal antibodies against PD-L1 or PD-1 have been approved for the treatment of multiple tumor histologies1,2 Oral, small-molecule PD-L1 inhibitors Are potent and selective
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: